Newron Pharmaceuticals S.p.A. (NP5.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR

Add to watchlist

10.52

+0.22

(+2.14%)

As of 08:03AM CEST. Market open.

Loading interactive chart...

Business Wire
Newron Announces Positive Top-line Results From Potentially Pivotal Phase II/III Study 008A With Evenamide in Schizophrenia Patients
MILAN, April 30, 2024--Newron announces positive top-line results from potentially pivotal Phase II/III study 008A with evenamide in schizophrenia patients
Business Wire
Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)
MILAN, April 08, 2024--Newron presents existing evenamide study 014/015 data and future clinical development outlook for evenamide at 2024 SIRS Congress in Florence, Italy
Business Wire
Newron Presents 2023 Financial Results and Provides 2024 Outlook
MILAN, March 19, 2024--Newron Pharmaceuticals announces 2023 year-end financial results and provides 2024 business outlook.